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Background: Peroxisome proliferator-activated receptor gamma (PPARγ) agonists are clinically used to coun-
teract hyperglycemia. However, so far experienced unwanted side effects, such as weight gain, promote the
search for new PPARγ activators.
Methods: We used a combination of in silico, in vitro, cell-based and in vivo models to identify and validate
natural products as promising leads for partial novel PPARγ agonists.
Results: The natural product honokiol from the traditional Chinese herbal drug Magnolia bark was in silico
predicted to bind into the PPARγ ligand binding pocket as dimer. Honokiol indeed directly bound to puriﬁed
PPARγ ligand-binding domain (LBD) and acted as partial agonist in a PPARγ-mediated luciferase reporter
assay. Honokiol was then directly compared to the clinically used full agonist pioglitazone with regard to
stimulation of glucose uptake in adipocytes as well as adipogenic differentiation in 3T3-L1 pre-adipocytes
and mouse embryonic ﬁbroblasts. While honokiol stimulated basal glucose uptake to a similar extent as
pioglitazone, it did not induce adipogenesis in contrast to pioglitazone. In diabetic KKAy mice oral application
of honokiol prevented hyperglycemia and suppressed weight gain.
Conclusion: We identiﬁed honokiol as a partial non-adipogenic PPARγ agonist in vitro which prevented
hyperglycemia and weight gain in vivo.
General signiﬁcance: This observed activity proﬁle suggests honokiol as promising new pharmaceutical lead
or dietary supplement to combat metabolic disease, and provides a molecular explanation for the use of
Magnolia in traditional medicine.© 2013 The Authors. Published by Elsevier B.V. All rights reserved.A, analysis of variance; ATCC,
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Sedentary lifestyle with low physical activity and high caloric in-
take promotes obesity, the metabolic syndrome, and type 2 diabetes,
which pose a major risk for the individual's quality of life and a bur-
den to the health care systems of industrialized societies. Peroxisome
proliferator activated receptor gamma (PPARγ) agonists are clinically
used to combat hyperglycemia common to these pathological condi-
tions and to alleviate related comorbidities [1–3]. Generally, PPARs
are nuclear receptors and ligand-dependent transcription factors
which control lipid and glucose metabolism [4–7]. Upon ligand bind-
ing, PPARs form heterodimers with the retinoid X receptor (RXR), an-
other nuclear receptor, and bind to response elements located in the
promoter region of their target genes [8]. After recruitment of nuclear
receptor coactivators [9,10] further chromatin rearrangement tran-
scription is initiated [11]. From the three known subtypes of PPAR
(α, β/δ, and γ), PPARγ is the best studied. It is expressed in adipose
tissue, lung, large intestine, kidney, liver, heart, and macrophagesserved.
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and lipid metabolism renders PPARγ a valid pharmacological target
for combating metabolic diseases [13,14]. Currently available full
PPARγ agonists represented by thiazolidinediones (e.g. pioglitazone)
are clinically effective, but they have serious side- and off-target
effects (e.g. weight gain or edema formation), urging the retrieval of
new PPARγ agonists. Ligands acting as partial agonists induce
submaximal receptor activation and have been demonstrated to
retain beneﬁcial anti-diabetic properties with reduced side effects.
Despite lower activation of the receptor, they are still able to induce
PPARγ target genes responsible for the anti-hyperglycemic and insu-
lin sensitizing, but not for the unwanted PPARγ actions [15,16]. The
reason for this is not entirely understood. However, it is conceivable
that partial agonists may elicit a different conformation of the receptor–
ligand complex that leads—by altered recruitment of transcriptional
co-activators and repressors—to a more restricted set of expressed target
genes compared to full agonists.
Using a computer-aided approach we have recently identiﬁed
neolignans as a novel class of partial agonists occupying the PPARγ
ligand-binding domain as dimers [17]. The hereby generated and opti-
mized in silico tools now enabled us to identify and further characterize
the neolignan honokiol, a major bioactive constituent of the traditional
Chinese herbal drug Magnolia bark, as novel non-adipogenic par-
tial PPARγ activator. The previously identiﬁed neolignans exhibit
PPARγ-dependent adipogenic properties similar to pioglitazone [17].
In contrast, we show in this work that the newly identiﬁed PPARγ
partial agonist honokiol does not trigger adipogenesis in two in vitro
cell systems and prevents weight gain in the murine KKAy in vivo
diabetes model, while retaining anti-hyperglycemic activity in vitro
and in vivo.
2. Materials and methods
2.1. Chemicals, cell culture reagents, and plasmids
Fetal calf serum (FCS), newborn bovine serum (NBS) and
Dulbecco's modiﬁed Eagle's medium (DMEM) were from Lonza
(Basel, Switzerland). Pioglitazone used for all experiments except in
vivo tests was from Molekula Ltd. (Shaftesbury, UK). All other
chemicals were from Sigma-Aldrich (Vienna, Austria). The test com-
pounds were dissolved in dimethyl sulfoxide (DMSO), divided into al-
iquots and kept frozen until use. In all experiments, DMSO was used
as solvent control. For in vitro and cell-based assays, the ﬁnal concen-
tration of DMSO was kept ≤0.2%. The PPAR luciferase reporter plas-
mid (tk-PPREx3-luc) was a gift from Prof. Ronald M. Evans (Howard
Hughes Medical Institute, La Jolla, CA) [18], the plasmid encoding en-
hanced green ﬂuorescent protein (pEGFP-N1) was from Clontech
(Mountain View, CA), and the plasmid encoding human PPARγ
(pSG5-PL-hPPAR-γ1) was a gift from Prof. Walter Wahli and Prof. Be-
atrice Desvergne (Center for Integrative Genomics, University of Lau-
sanne, Switzerland) [19].
2.2. Isolation of honokiol
880 g powdered bark of Magnolia ofﬁcinalis (Plantasia, Oberndorf,
Austria; lot: 710786) was exhaustively macerated with
dichloromethane (8.0 l, 12 times) at room temperature, yielding
96.8 g crude extract. 80.0 g extract was separated by ﬂash silica gel
column chromatography (400 g silica gel 60, 40–63 μm, Merck,
VWR, Darmstadt, Germany; 41 × 3.5 cm) using a petroleum ether–
acetone gradient with an increasing amount of acetone. The eluate
was collected in portions of 20 ml and analyzed by TLC. Comparable
portions were combined to 18 fractions (A1–A18). Fraction A8
(5.761 g) was further separated by Sephadex LH-20-column chroma-
tography (CC) using methanol as mobile phase. Fractions were mon-
itored by TLC and combined according to their composition to 15fractions (B1–B15). Fraction B8 (810 mg) was further puriﬁed by
HSCCC with a mixture of PE–EtOAc–MeOH–H20 1 + 0.5 + 1 + 0.5
(v/v/v/v) using the upper layer as mobile phase. HSCCC was set to the
tail to headmode with 800 rpm and a ﬂow rate of 1 ml/min. The eluate
was collected in portions of 5 ml and combined to 18 fractions (C1–
C18). Fraction C11 (eluted at 495–580 ml; 249 mg) was further puri-
ﬁed by Sephadex LH-20-CC using a dichloromethane–acetone mixture
(85 + 15, v/v) as mobile phase to yield 217.54 mg of honokiol in a pu-
rity (HPLC) of N98%. Identity of the obtained compound was proven
by comparison of 1- and 2D NMR-spectra with literature [20] and
by LC–MS analysis. The obtained NMR- and LC–MS-data are provid-
ed as online supplement (supplemental Table S1 and supplemental
Figs. S1–S4). The isolated honokiol was used for all in vitro
bioassays.
2.3. PPARγ luciferase reporter gene transactivation
HEK-293 cells (ATCC, Manassas, VA) were grown in DMEM
supplemented with 2 mM glutamine, 100 U/ml benzylpenicillin,
100 μg/ml streptomycin, and 10% FBS. The cells were seeded in
10-cm dishes at a density of 6 × 106 cells/dish for 18 h, and then
transfected by the calcium phosphate precipitation method with
4 μg of PPARγ expression plasmid, 4 μg of reporter plasmid
(tk-PPREx3-luc), and 2 μg of pEGFP-N1 as internal control. Six hours
later, the cells were reseeded in 96-well plates (5 × 104 cells/well)
in DMEM without phenol red with 5% charcoal-stripped FBS, gluta-
mine and antibiotics. The cells were treated as indicated and incubat-
ed for 18 h. After cell lysis, the luminescence of the ﬁreﬂy luciferase
and the ﬂuorescence of EGFP were quantiﬁed on a GeniosPro plate
reader (Tecan, Grödig, Austria). The luminescence signals were nor-
malized to the EGFP-derived ﬂuorescence, to account for differences
in cell number or transfection efﬁciency. Neither pioglitazone nor
honokiol interfered with the luciferase assay background determined
upon transfection of the cells with tk-PPREx3-luc in the absence of
PPARγ.
2.4. PPARγ competitive ligand binding
The LanthaScreen® time-resolved ﬂuorescence resonance energy
transfer (TR-FRET) PPARγ competitive binding assay (Invitrogen,
Lofer, Austria) was performed using the manufacturer's protocol.
The test compounds dissolved in DMSO or solvent vehicle (DMSO)
alone were incubated together with the human PPARγ LBD tagged
with GST, terbium-labeled anti-GST antibody and ﬂuorescently la-
beled PPAR ligand (Fluormone Pan-PPAR Green). In this assay, the
ﬂuorescently labeled ligand is binding to the human PPARγ LBD,
which brings it in close spatial proximity to the terbium-labeled
anti-GST antibody. Excitation of the terbium at 340 nm results in en-
ergy transfer (FRET) and partial excitation of the ﬂuorescent PPAR li-
gand, followed by emission at 520 nm. Test-compounds binding to
the human PPARγ LBD are competing with the ﬂuorescently labeled
ligand and displacing it, resulting in a decrease of the FRET signal.
The signal obtained at 520 nm is normalized to the signal obtained
from the terbium emission at 495 nm; therefore, the decrease in the
520 nm/495 nm ratio is used as a measure for the ability of the tested
compounds to bind to the human PPARγ LBD. Neither pioglitazone
nor honokiol interfered with the background 520 nm/495 nm ﬂuo-
rescence in the absence of PPARγ LBD.
2.5. Induction of adipogenic differentiation
3T3-L1 preadipocytes were subcultivated in DMEM (containing
2 mM glutamine, 100 U/ml benzylpenicillin, 100 μg/ml streptomycin)
plus 10% NBS. For differentiation experiments they were grown till
conﬂuency in 12-well plates. Two days later cells were treated with
DMEM/10% FCS (negative control), DMEM/10% FCS/1 μg/ml insulin
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nists (1, 3 and 10 μM). An additional set of cells exposed to the
highest concentration of the respective agonist was pretreated
with the PPARγ antagonist BADGE (50 μM) for 30 min in order to as-
sess the PPARγ-dependency of an observable lipid accumulation. All
wells contained 0.2% DMSO. Medium was renewed every other day.
After eight days, lipid accumulation (asmeasure of adipogenic differ-
entiation) was determined by OilRed O staining. Solubilized dye was
quantiﬁed at 550 nm. Experiments were performed at least three
times.
Immortalized mouse embryonic ﬁbroblasts (MEF) (kind gift of
Prof. Thomas Kensler, University of Pittsburgh) were differentiated
into adipocytes as described [21] with minor modiﬁcations. Cells
were grown in DMEM/10% FCS till conﬂuency (12-well plate). Two
days later, cells were treated with DMEM/10% FCS (negative control)
or basal MEF diff (differentiation) cocktail (1 μg/ml insulin/200 μM
isobutylmethylxanthine (IBMX)/500 nM dexamethasone/25 ng/ml
bone morphogenic protein (BMP) 4) in the presence and absence
of PPARγ agonists (1–10 μM). An additional set of cells exposed to
the highest concentration of the respective agonist was pretreated
with the PPARγ antagonist BADGE (50 μM) for 30 min in order to as-
sess the PPARγ-dependency of a potential lipid accumulation. All
wells contained 0.2% DMSO. After three days, the medium was
changed to DMEM/10% FCS for control cells and to DMEM/10% FCS/
1 μg/ml ± PPARγ agonists (1–10 μM) for differentiating cells, re-
spectively. After an overall differentiation time of nine days, lipid ac-
cumulation was determined by OilRed O staining (see supplemental
Fig. S6). Solubilized dyewas quantiﬁed at 550 nm. Experiments were
performed at least three times.
2.6. OilRed O staining
Cells in plates were ﬁxed with 10% formaldehyde for at least 1 h,
washed with 60% isopropanol and dried, before ﬁltered OilRed O solu-
tion (2% OilRed O in 60% isopropanol) was added for 10 min. After
washing off the excessive dye with water, photos were taken, and
bound dye was solubilized with equal volumes of 100% isopropanol
per well and immediately photometrically quantiﬁed at 550 nm in a
spectrophotometer (Tecan, Grödig, Austria).
2.7. 2-Deoxy-D-(1H3)-glucose uptake assay in adipocytes
Superconﬂuent 3T3-L1 preadipocytes were differentiated into
mature adipocytes for 10 days (2 days in DMEM (containing 2 mMglu-
tamine and antibiotics) supplemented with 10% FCS, 500 μM IBMX,
1 μg/ml insulin and 500 nM dexamethasone followed by 2 days in
DMEM/10% FCS/1 μg/ml insulin and 6 days in DMEM/10% FCS), and
incubated with the test compounds or solvent vehicle for 24 h at
37 °C. Before the experiment, cells were incubated for 1 h in KRH
buffer (50 mM HEPES, 136 mM NaCl, 23.5 mM KCl, 1.25 mM MgSO4,
1.25 mM CaCl2 and 0.1% BSA). After an additional KRH buffer change,
cells were allowed to rest for 10 min, then glucose uptake was initiated
by addition of 2-deoxy-D-glucose spikedwith 2-deoxy-D-(1H3)-glucose
(ﬁnal concentrations of 0.1 mM and 0.45 μCi/ml). After 15 min the
reaction was stopped by three rapid washes with ice-cold PBS. The
glucose uptake rate was determined by liquid scintillation counting
(PerkinElmer, Waltham, MA, USA) of cell lysates (0.05 N NaOH in PBS)
and normalized to protein content assessed by the Bradford protein
assay and uptake time (to obtain incorporated mol glucose per mg pro-
tein and minute).
2.8. Animal experiments
The KKAy mice represent a model for obesity and type 2 diabetes,
with spontaneous development of hyperglycemia, hyperinsulinemia,
glucose intolerance, and obesity [22,23]. KKAy mice (female, SPFgrade, qualiﬁcation license No. SCXK (Beijing) 2009-0004, certiﬁcation
No. 0237501, utilization license No. SYXK (Military) 2007-030), and
C57B1/6J mice were all supplied by Beijing Hua Fu Kang Bio-technology
Company Ltd. All animal tests were conducted with full compliance
with local, national, and ethical principles and authority regulations.
The KKAy mice were raised in a SPF experimental room, and served
standard high fat diet (composed from sucrose, pork lard, egg yolk
powder, and ordinary feed in ratio of 10:10:10:7; from Beijing Hua
Fu Kang Bio-technology Company Ltd.) and freely available drinking
water. Age-mated C57B1/6J mice were served ordinary feed and
unrestricted drinking water. When the blood glucose of KKAy mice
reached ≥13.9 mM (conﬁrming the successful establishment of the
diabetic model) the animals were separated into four groups (10 ani-
mals per group): (1.) “No treatment” group received through oral
gavage administration sterilized water (0.1 ml/10 g body weight) once
per day for 35 days; (2.) “Vehicle” group received alcoholic (0.5%)
CMCNa (5%) solution (0.1 ml/10 g body weight); (3.) “Pioglitazone”
group received through oral gavage pioglitazonehydrochloride solution
(Santa Cruz Biotechnology, Heidelberg, Germany; 1 mg/ml alcoholic
(0.5%)) CMCNa (5%) solution (0.1 ml/10 g body weight), once per day
(10 mg/kg/d) for 35 days; (4.) “Honokiol” group received through
oral gavage honokiol solution (Carbosynth, Compton, UK; 10 mg/ml al-
coholic (0.5%)) CMCNa (5%) solution (0.1 ml/10 g body weight) once
per day (the 100 mg/kg/d treatment dosewas chosen because that con-
centration demonstrated to have a clear effect in preliminary experi-
ments), for 35 days. The C57B1/6J control group received through oral
gavage administration sterilized water (0.1 ml/10 g body weight),
once per day for 35 days. ACCU-CHEK advantage blood glucose detec-
tion system fromRochewas used to determine the blood glucose levels.
Glucose tolerance test was performed after 35 days of the indicated
treatments following a 3 h of fasting. The blood glucose was measured
before (0 min) or 60 min and 120 min after administration of 2.5 g/kg
glucose. Area under curve (AUC) was estimated using the formula
AUC = 1 / 2(0 h + 1 h) ∗ 0.5 + 1 / 2(1 h + 2 h) ∗ 1.5. To determine
insulin levels (right after the 35 day treatment period) the rat/mouse In-
sulin ELISA Kit fromMillipore was used according to the manufacturers'
instructions.
No differences between the treatment groups were detected in
terms of routine activity of the animals, hair condition, food intake
and water intake.
2.9. Molecular docking
Docking experiments of honokiol into the hPPARγ ligand binding
domain (Protein Data Bank, www.pdb.org, PDB ID: 2VSR [24]) were
performed using the CDOCKER module of Discovery Studio 2.5
(www.accelrys.com) with default settings. For the ﬁrst ligand, the
binding site was deﬁned as a 9 Å sphere, centered on the guanidine
carbon of Arg288. The binding site for the second ligand was deﬁned
as an 8 Å sphere, centered on the sulfur atom of Cys285. Predicted
binding poses were visualized and ligand–protein interactions ana-
lyzed with LigandScout 3.03 (www.inteligand.com).
2.10. Statistical methods and data analysis
Statistical analyseswere donewith the GraphPad Prism software ver-
sion 4.03. One-way or two way analysis of variance (ANOVA) with
Bonferroni post hoc test was used to determine statistical signiﬁcance.
Nonlinear regression (sigmoidal dose response) was used to calculate
the EC50 values and maximal fold activation. Ki values of the investigated
compounds in the receptor binding assay were calculated with the
Cheng–Prusoff equation: (Ki) = IC50 / (1 + L / KD)), where IC50 is the
concentration of the competitor that produces 50%displacement of the li-
gand, L is the concentration of Fluormone™ Pan-PPAR Green used in the
assay (5 nM), and KD is the binding constant (2.8 nM) of Fluormone™
Pan-PPAR Green to PPARγ-LBD [25].
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3.1. Identiﬁcation of honokiol as a novel partial PPARγ agonist
We aimed to characterize novel partial PPARγ ligands, which can
reduce blood sugar levels without inducing weight gain. Using the
pharmacophore model collection previously developed [26], we
have recently identiﬁed several neolignans as representatives of a
novel class of partial PPARγ agonists binding to the receptor LBD
as dimers [17]. In the present study another structurally similar
neolignan, the natural product honokiol (Fig. 1A), was predicted
by molecular docking to also bind to PPARγ in a dimeric mode
(Fig. 1B). In order to conﬁrm that honokiol indeed binds to PPARγ
we performed a competitive FRET-based ligand binding assay with
the puriﬁed human PPARγ LBD. Honokiol directly bound to the puri-
ﬁed human PPARγ LBD in vitro (Fig. 2A; Ki = 22.86 μM), although
weaker than pioglitazone (Figs. 1A and 2A; Ki = 0.69 μM), which
served as a reference full agonist for all conducted experiments.
Honokiol also bound to the LBDs of PPARα and PPARβ/δ but only at
considerably (three to four-fold) higher concentrations than requiredFig. 1. Chemical structures (A) of pioglitazone and honokiol, and honokiol modeled in the PP
tacts, red and green arrows hydrogen bonds between honokiol and Cys285 and Ser289, res
Fig. 2. PPARγ receptor binding and luciferase reporter transactivation of honokiol. (A) PPARγ
DMSO and then mixed with a buffer solution containing the human PPARγ LBD tagged with
1 h of incubation, the ability of the test compounds to bind to the PPARγ LBD and thus disp
ratio 520 nm/495 nm upon excitation at 340 nm. Each data point represents the mean ±
duplicate. (B) Inﬂuence of honokiol on human PPARγ-mediated luciferase reporter ge
full-length human PPARγ, a reporter plasmid containing PPAR-response element coupled to
concentrations of honokiol and pioglitazone for 18 h. Luciferase activity was normalized to t
with the negative control (DMSO vehicle treatment). The data shown are means ± SEM offor PPARγ binding (data not shown). In a next step we examined
honokiol for its transactivation potential using a PPARγ-driven lucif-
erase reporter gene assay. Honokiol hereby displayed partial PPARγ
agonism. It activated the receptor with an EC50 value of 3.9 μM and
reached maximally two-fold activation compared to 12-fold maximal
activation with an EC50 value of 0.3 μM by the full agonist pioglitazone
in the same system (Fig. 2B).3.2. Honokiol stimulates basal glucose uptake in 3T3 adipocytes
In order to assess PPARγ agonism in a functional cell model with en-
dogenous levels of PPARγ, we investigated the potential anti-
hyperglycemic activity of honokiol and pioglitazone in mature 3T3-L1
adipocytes. We incubated the cells with different non-toxic concentra-
tions of pioglitazone or honokiol (1–10 μM, supplemental Fig. S5) for
24 h and determined the basal cellular glucose uptake rate. As seen in
Fig. 3, both compounds enhanced the cellular glucose uptake in adipo-
cytes in a concentration dependentmanner and also to a comparable ex-
tent. At a concentration of 10 μM both compounds approximatelyARγ ligand-binding pocket (B). Yellow spheres mark hydrophobic protein–ligand con-
pectively.
binding of honokiol. Serial dilutions of the honokiol and pioglitazone were prepared in
GST, a terbium-labeled anti-GST antibody, and ﬂuorescently labeled PPAR agonist. After
lace the ﬂuorescently labeled ligand was estimated from the decrease of the emission
standard error of the mean (SEM) from three independent experiments performed in
ne transactivation. HEK-293 cells, transiently transfected with a plasmid encoding
a luciferase reporter, and EGFP as internal control, were stimulated with the indicated
he EGFP-derived ﬂuorescence, and the result was expressed as fold induction compared
three independent experiments each performed in quadruplicate.
Fig. 3. Basal glucose uptake rate upon treatment with honokiol in differentiated adipo-
cytes. Differentiated 3T3-L1 adipocytes were treated with DMSO (solvent control; 0 μM)
or different concentrations of pioglitazone (Pio) and honokiol (Hon) (1–10 μM) for 24 h
before the basal cellular glucose uptake rate was determined as described in detail in
the “Materials and methods” section. The bar graph depicts compiled results of three in-
dependent experiments (means ± SEM, *p b 0.05, statistically different to DMSO control
group, ANOVA, Bonferroni post test).
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3.3. Honokiol does not induce adipogenic differentiation in vitro
We further assessed the adipogenic potential of honokiol and
pioglitazone. For this, we chose two different cellular adipogenesis
models [27]. In both 3T3-L1 preadipocytes (Fig. 4A) and immortal-
ized mouse embryonic ﬁbroblasts (Fig. 4B) pioglitazone signiﬁcantly
enhanced adipogenic differentiation in a concentration-dependent
manner. The induction of differentiation by pioglitazone was
PPARγ-dependent and not an off-target result of pioglitazone treat-
ment as it was blunted by co-treatment with the known PPARγ an-
tagonist BADGE. Honokiol, even at the highest test concentration
(10 μM), did not lead to a markedly enhanced formation of intracel-
lular lipid droplets above basal levels (see also supplemental Fig. S6).
3.4. Honokiol prevents in vivo exacerbation of hyperglycemia and weight
gain in the KKAy murine diabetes model
So far we have shown that honokiol binds to PPARγ and is a partial
(eliciting submaximal activation) and apparently selective (hypergly-
cemic but not adipogenic) PPARγ modulator in vitro. We went on toA B
Fig. 4. Adipogenic potential of honokiol. 3T3-L1 preadipocytes (A) and mouse embryonic ﬁb
tiate into adipocytes and accumulate lipid in a PPARγ-dependent way as described in detail
tiation medium, Pio: pioglitazone (0–10 μM), Hon: honokiol (1–10 μM), Diff Cocktail: ba
morphogenic protein 4). BADGE (50 μM) was used as PPARγ antagonist. After staining the
Fig. S6). Bound dye was solubilized and quantiﬁed spectrophotometrically at 550 nm. The b
iments (means ± SEM, *p b 0.05, statistically different to “INS” and “Diff cocktail”, respectichallenge these promising ﬁndings with the in vivo situation. For
this, we chose diabetic KKAy mice which are characterized by gradu-
ally worsening obesity and hyperglycemia. We administered
honokiol (100 mg/kg), pioglitazone (10 mg/kg), or vehicle for
35 days to these mice. Whereas both pioglitazone and honokiol suc-
cessfully prevented exacerbation of hyperglycemia (Fig. 5A), only
honokiol also signiﬁcantly suppressed weight gain (Fig. 5B). Further-
more, honokiol signiﬁcantly (p b 0.001) improved the glucose toler-
ance and the insulin levels of treated animals (Table 1). These
results ﬁt well with the in vitro experiments outlining honokiol as
an efﬁcient non-adipogenic blood glucose lowering agent, although
further in vivo experiments, particularly with lower administration
doses, are required to better estimate its therapeutic potential.
4. Discussion
We report in this study the identiﬁcation and characterization of
the natural product honokiol as a novel non-adipogenic partial
PPARγ agonist. Interestingly, honokiol is one of the main bioactive
constituents (1–5% content) of the traditional Chinese herbal drug
Magnolia bark (Cortex Magnoliae, Hou Po), used to treat metabolic
disease among others [28], and may thus contribute to the beneﬁcial
properties of this herbal remedy via partial activation of PPARγ.
Honokiol is a representative of the chemical class of neolignans,
which we recently identiﬁed as novel partial PPARγ agonists binding
to the receptor LBD as dimers [17]. Shortly after our ﬁndings,
magnolol, one of our investigated neolignan-type PPARγ agonists,
was shown to also bind to RXRα [29]. The co-crystal structures with
PPARγ and RXRα revealed a unique mode of dual PPARγ/RXR
agonism by magnolol [29]. In addition to the partial PPARγ agonism
that we demonstrate here (Fig. 2A,B), honokiol has recently also
been shown to directly bind to RXR [30]. Honokiol therefore conforms
to the dual PPARγ/RXR binding mode demonstrated for the structur-
ally similar magnolol [29]. However, whereas all previously described
neolignans, including the dual PPARγ/RXR agonist magnolol, induced
PPARγ-dependent lipid accumulation in 3T3-L1 adipocytes similar to
pioglitazone [17], honokiol did not (Fig. 4) and therefore emerges as
superior novel PPARγ modulator. Interestingly, in contrast to our
ﬁndings Choi et al. [31] reached the conclusion that honokiol did
not directly bind to PPARγ and induced adipogenic differentiation in
3T3-L1 preadipocytes. One reason for this discrepancy could be the
different ranges of used honokiol concentrations. Whereas Choi et
al. tested honokiol up to 30 μM, we have also investigated the effectroblasts (B) were grown in 12-well plates to superconﬂuency and induced to differen-
in the “Materials and methods” section (INS: insulin-containing 3T3-L1 basal differen-
sal MEF differentiation cocktail containing insulin, IBMX, dexamethasone and bone
cells with the lipophilic dye OilRed O the plates were photographed (see supplemental
ar graphs depict compiled results of four (3T3-L1) or three (MEF) independent exper-
vely; ANOVA, Bonferroni post-test).
Fig. 5. Effect of honokiol on the blood glucose and body weight of diabetic KKAy mice. Blood glucose (A) and body weight (B) of KKAy mice administered orally with honokiol
(100 mg/kg/day), pioglitazone (10 mg/kg/day) or vehicle for 35 days is presented (box and whisker plots representing median, upper and lower quartiles, and lowest and highest
detected values. ***p b 0.001, **p b 0.01, *p b 0.05 (n = 10, one-way ANOVA/Bonferroni)).
4818 A.G. Atanasov et al. / Biochimica et Biophysica Acta 1830 (2013) 4813–4819of the compound at several fold higher concentrations (Fig. 1A). An-
other relevant consideration is that those authors based the exclusion
of honokiol as direct PPARγ-binder on a negative result from a
TRAP220/DRIP-2 coactivator peptide recruitment assay [31]. An alter-
native explanation for that observation could be that the binding of
honokiol to PPARγ LBD induces a receptor–ligand complex with a
conformation that is not optimal for recruitment of the TRAP220/
DRIP-2 coactivator peptide in particular. In support of the latter inter-
pretation, our receptor-binding assay (Fig. 2A) unbiasedly shows that
honokiol is able to displace ﬂuorescently labeled PPARγ agonist from
the LBD and thus directly binds to the ligand binding pocket of PPARγ.
It is well known that different ligands induce receptor–ligand com-
plexes with different conformations, leading to the recruitment of
distinct sets of coactivators to PPAR-γ and expression of distinct
sets of genes [32,33]. In line, another partial PPARγ agonist,
MBX-102/JNJ39659100, was previously demonstrated to be unable
to trigger TRAP220 recruitment to PPARγwhile retaining antidiabetic
properties without inducing weight gain [34]. To carefully investigate
a potential pro-adipogenic activity of honokiol we used two different
in vitro adipogenesis models. Whereas the full agonist pioglitazone
induced a potent PPARγ-dependent adipogenic differentiation in
both cellular models, honokiol did not display adipogenic properties
(Fig. 4A and B). Moreover, the favorable activity proﬁle observed in
vitro was further conﬁrmed in vivo in the diabetic KKAy mouse
model in which honokiol not only prevented rising hyperglycemia
similar to pioglitazone (Fig. 5A) but also suppressed weight gain
(Fig. 5B) and clearly negatively inﬂuenced adipogenesis in ourTable 1
Effect of honokiol or pioglitazone treatment on the glucose tolerance of KKAy mice. Glucose t
indicated treatments following 3 h of fasting. The blood glucose was measured before (0 m
using the formula AUC = 1 / 2(0 h + 1 h) ∗ 0.5 + 1 / 2(1 h + 2 h) ∗ 1.5. The shown dat
KKAy: vehicle group (ANOVA/Bonferroni).
Blood glucose (mM)
0 min 60 min
C57B1/6J 6.11 ± 1.03*** 6.83 ± 1.02***
KKAy: no treatment 29.57 ± 4.29n.s. 30.6 ± 3.02n.s.
KKAy: vehicle 27.25 ± 3.25 29.4 ± 2.71
KKAy: pioglitazone 19.54 ± 6.43*** 19.96 ± 5.30***
KKAy: honokiol 15.59 ± 2.71*** 22.94 ± 5.51⁎⁎experiments. At the current stage, however, it cannot be excluded that
proteins other than PPARγ contribute to the beneﬁcial in vivo effects
of honokiol. Further support for PPARγ activation by honokiol in vivo
may be provided in a recent work from Diano et al. who show that
honokiol administration mimics the modulatory effect of rosiglitazone
on the activation of hypothalamic neuronal circuits involved in body
weight control [35]. However, this observation was then interpreted
as a consequence of the ROS scavenging properties of honokiol, and
the possibility that the compound could act as a direct activator of
PPARγ was not considered by the authors.
Overall, the here identiﬁed partial PPARγ activation pattern, in
combination with suppression of hyperglycemia and weight gain,
makes honokiol an interesting natural product with a good poten-
tial to be further explored as pharmaceutical lead or dietary
supplement.
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